# Extension in AS: Sustainability of Benefits, Safety and Tolerability

> **NCT01863732** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 274 (actual)

## Conditions studied

- Spondylitis, Ankylosing

## Interventions

- **BIOLOGICAL:** Secukinumab
- **OTHER:** Placebo (Pbo)

## Key facts

- **NCT ID:** NCT01863732
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-06
- **Primary completion:** 2018-03-16
- **Final completion:** 2018-03-16
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2019-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01863732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01863732, "Extension in AS: Sustainability of Benefits, Safety and Tolerability". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01863732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*